FDA approves new kidney cancer drug combination
FDA approves new kidney cancer drug combination
Updated at: September 28, 2026 at 12:15 AM
On September 24, 2026, the U.S.
Food and Drug Administration (FDA) reached a medical milestone by approving a new drug combination for patients with advanced kidney cancer.
The treatment involves pairing belzutifan (WELIREG) with lenvatinib (LENVIMA) for adults with advanced renal cell carcinoma who have already undergone treatment with immune checkpoint inhibitors.
The approval follows the results of the phase 3 LITESPARK-011 clinical trial, which compared this combination against standard treatments.
While the combination offers new hope, patients and providers must carefully manage potential side effects, including hypertension, anemia, and cardiac dysfunction.
By offering a non-immunotherapy strategy, this approval addresses a critical medical need, providing a vital new option for patients navigating the challenges of advanced kidney cancer.
